| [1] |
Clemens JQ, Erickson DR, Varela NP, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome[J]. J Urol, 2022, 208(1): 34-42. DOI: 10.1097/ju.0000000000002756.
|
| [2] |
|
| [3] |
|
| [4] |
Li J, Yi X, Ai J. Broaden horizons: the advancement of interstitial cystitis/bladder pain syndrome[J]. Int J Mol Sci, 2022, 23(23): 14594. DOI: 10.3390/ijms232314594.
|
| [5] |
Homma Y, Akiyama Y, Tomoe H, et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome[J]. Int J Urology, 2020, 27(7): 578-589. DOI: 10.1111/iju.14234.
|
| [6] |
Zhang Z, Liu P, Xue X, et al. The role of platelet-rich plasma in biomedicine: a comprehensive overview[J]. iScience, 2025, 28(2): 111705. DOI: 10.1016/j.isci.2024.111705.
|
| [7] |
Poulios E, Mykoniatis I, Pyrgidis N, et al. Platelet-rich plasma (PRP) improves erectile function: a double-blind, randomized, placebo-controlled clinical trial[J]. J Sexual Med, 2021, 18(5): 926-935. DOI: 10.1016/j.jsxm.2021.03.008.
|
| [8] |
Everts P, Onishi K, Jayaram P, et al. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020[J]. Int J Mol Sci, 2020, 21(20): 7794. DOI: 10.3390/ijms21207794.
|
| [9] |
Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder?[J]. Urologia, 2016, 83(Suppl 1): 11-14. DOI: 10.5301/uro.5000184.
|
| [10] |
Yu WR, Jhang JF, Jiang YH, et al. The pathomechanism and current treatments for chronic interstitial cystitis and bladder pain syndrome[J]. Biomedicines, 2024, 12(9): 2051. DOI: 10.3390/biomedicines12092051.
|
| [11] |
Green DP, Limjunyawong N, Gour N, et al. A mast-cell-specific receptor mediates neurogenic inflammation and pain[J]. Neuron, 2019, 101(3): 412-420.e3. DOI: 10.1016/j.neuron.2019.01.012.
|
| [12] |
Whitmore KE, Fall M, Sengiku A, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome[J]. Int J Urol, 2019, 26(Suppl 1): 26-34. DOI: 10.1111/iju.13971.
|
| [13] |
Shie JH, Kuo HC. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome[J]. BJU Int, 2011, 108(2 B): E136-E141.DOI: 10.1111/j.1464-410X.2010.09911.x.
|
| [14] |
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy[J]. Expert Rev Hematol, 2021, 14(1): 97-108. DOI: 10.1080/17474086.2021.1860002.
|
| [15] |
左秀芹, 尹飒飒, 谢惠敏, 等. 富血小板血浆在肌骨修复领域应用的适用性与相关规范[J]. 中国组织工程研究, 2021, 25(20): 3239-3245.
|
| [16] |
Cecerska-Heryć E, Heryć R, Wiśniewska M, et al. Regenerative potential of platelets in patients with chronic kidney disease[J]. Int Urol Nephrol, 2019, 51(10): 1831-1840. DOI: 10.1007/s11255-019-02190-6.
|
| [17] |
Mazzocca AD, McCarthy MB, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability[J]. J Bone Joint Surg Am, 2012, 94(4): 308-316. DOI: 10.2106/JBJS.K.00430.
|
| [18] |
Bielecki T, Dohan Ehrenfest DM, Everts PA, et al. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives[J]. Curr Pharm Biotechnol, 2012, 13(7): 1153-1162. DOI: 10.2174/138920112800624373.
|
| [19] |
Kuffler DP. Platelet-rich plasma promotes axon regeneration, wound healing, and pain reduction: fact or fiction[J]. Mol Neurobiol, 2015, 52(2): 990-1014. DOI: 10.1007/s12035-015-9251-x.
|
| [20] |
Wang Y, Che M, Xin J, et al. The role of IL-1β and TNF-α in intervertebral disc degeneration[J]. Biomed Pharmacother, 2020, 131: 110660. DOI: 10.1016/j.biopha.2020.110660.
|
| [21] |
Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins[J]. Blood, 2013, 121(8): 1276-1284. DOI: 10.1182/blood-2012-11-451229.
|
| [22] |
Xue C, Segabinazzi LGTM, Hall A, et al. Manual platelet-rich plasma production in donkeys by double centrifugation results in leukocyte-rich platelet-rich plasma compared to single centrifugation[J]. Am J Vet Res, 2025, 86(6): ajvr.25.01.0022. DOI: 10.2460/ajvr.25.01.0022.
|
| [23] |
|
| [24] |
|
| [25] |
Shin HS, Woo HM, Kang BJ. Optimisation of a double-centrifugation method for preparation of canine platelet-rich plasma[J]. BMC Vet Res, 2017, 13(1): 198. DOI: 10.1186/s12917-017-1123-3.
|
| [26] |
Croisé B, Paré A, Joly A, et al. Optimized centrifugation preparation of the platelet rich plasma: Literature review[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(2): 150-154. DOI: 10.1016/j.jormas.2019.07.001.
|
| [27] |
Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol, 2009, 27(3): 158-167. DOI: 10.1016/j.tibtech.2008.11.009.
|
| [28] |
Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates[J]. Regen Med, 2013, 8(5): 645-658. DOI: 10.2217/rme.13.59.
|
| [29] |
Jiang YH, Jhang JF, Lin TY, et al. Therapeutic efficacy of intravesical platelet-rich plasma injections for interstitial cystitis/bladder pain syndrome-a comparative study of different injection number, additives and concentrations[J]. Front Pharmacol, 2022, 13: 853776. DOI: 10.3389/fphar.2022.853776.
|
| [30] |
Beitia M, Delgado D, Mercader J, et al. Action of platelet-rich plasma on in vitro cellular bioactivity: more than platelets[J]. Int J Mol Sci, 2023, 24(6): 5367. DOI: 10.3390/ijms24065367.
|
| [31] |
Etulain J, Mena HA, Meiss RP, et al. An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties[J]. Sci Rep, 2018, 8(1): 1513. DOI: 10.1038/s41598-018-19419-6.
|
| [32] |
Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-beta receptor function[J]. Trends Cell Biol, 2009, 19(8): 385-394. DOI: 10.1016/j.tcb.2009.05.008.
|
| [33] |
Roberts JH, Halper J. Growth factor roles in soft tissue physiology and pathophysiology[M]// Progress in Heritable Soft Connective Tissue Diseases. Cham: Springer, 2021: 139-159. DOI: 10.1007/978-3-030-80614-9_6.
|
| [34] |
Kuffler DP. Techniques and factors for reducing chronic neuropathic pain: a review[J]. Neural Regen Res, 2026, 21(4): 1353-1358. DOI: 10.4103/nrr.nrr-d-22-00015.
|
| [35] |
Kuffler DP. Platelet-rich plasma and the elimination of neuropathic pain[J]. Mol Neurobiol, 2013, 48(2): 315-332. DOI: 10.1007/s12035-013-8494-7.
|
| [36] |
|
| [37] |
Chen NF, Sung CS, Wen ZH, et al. Therapeutic effect of platelet-rich plasma in rat spinal cord injuries[J]. Front Neurosci, 2018, 12: 252. DOI: 10.3389/fnins.2018.00252.
|
| [38] |
Cl K, Jeyaraman M, Jeyaraman N, et al. Antimicrobial effects of platelet-rich plasma and platelet-rich fibrin: a scoping review[J]. Cureus, 2023, 15(12): e51360.DOI: 10.7759/cureus.51360.
|
| [39] |
Tornavaca O, Chia M, Dufton N, et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation[J]. J Cell Biol, 2015, 208(6): 821-838. DOI: 10.1083/jcb.201404140.
|
| [40] |
Wu Y, Chen L, Xu M, et al. Platelet-rich plasma improves cyclophosphamide-induced interstitial cystitis in rat models through the toll-like receptor 4/nuclear factor-kappa B signalling pathway[J]. Clin Exp Nephrol, 2025, 29(7): 995-1004. DOI: 10.1007/s10157-025-02660-5.
|
| [41] |
Dönmez Mİ, İnci K, Zeybek ND, et al. The early histological effects of intravesical instillation of platelet-rich plasma in cystitis models[J]. Int Neurourol J, 2016, 20(3): 188-196. DOI: 10.5213/inj.1632548.274.
|
| [42] |
Jiang YH, Kuo YC, Jhang JF, et al. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis[J]. Sci Rep, 2020, 10(1): 15218. DOI: 10.1038/s41598-020-72292-0.
|
| [43] |
Jiang JF, Jiang YH, Kuo HC. Current understanding of the pathophysiology and novel treatments of interstitial cystitis/bladder pain syndrome[J]. Biomedicines, 2022, 10(10): 2380. DOI: 10.3390/biomedicines10102380.
|
| [44] |
Kiuchi H, Tsujimura A, Takao T, et al. Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: its association with pain severity and glomerulations[J]. BJU Int, 2009, 104(6): 826-831. DOI: 10.1111/j.1464-410x.2009.08467.x.
|
| [45] |
Jhang JF, Jiang YH, Hsu YH, et al. Improved urothelial cell proliferation, cytoskeleton and barrier function protein expression in the patients with interstitial cystitis/bladder pain syndrome after intravesical platelet-rich plasma injection[J]. Int Neurourol J, 2022, 26(Suppl 1): S57-S67. DOI: 10.5213/inj.2142100.050.
|
| [46] |
Yu WR, Jiang YH, Jhang JF, et al. Repeated intravesical injections of platelet-rich plasma are safe and effective in the treatment of interstitial cystitis/bladder pain syndrome[J]. Tzu Chi Med J, 2025, 37(1): 72-79. DOI: 10.4103/tcmj.tcmj_166_24.
|
| [47] |
El Hefnawy AS, Hasan MAA, El Sawy E, et al. Intravesical instillation of platelet-rich plasma for treatment of interstitial cystitis/bladder pain syndrome: a pilot study[J]. Curr Urol, 2024, 18(1): 49-54. DOI: 10.1097/CU9.0000000000000156.
|
| [48] |
Yoshimura N, Homma Y, Tomoe H, et al. Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: a multicenter, randomized, double-blind, placebo-controlled, clinical study[J]. Int J Urol, 2021, 28(5): 545-553. DOI: 10.1111/iju.14505.
|
| [49] |
Jhang JF, Yu WR, Kuo HC. Comparison of the clinical efficacy and adverse events between intravesical injections of platelet-rich plasma and botulinum toxin a for the treatment of interstitial cystitis refractory to conventional treatment[J]. Toxins, 2023, 15(2): 121. DOI: 10.3390/toxins15020121.
|
| [50] |
|